SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Hepatitis C Diagnostic - Barrier to Effective Linkage to Care within Georgian Hepatitis C Elimination Program | Guranda Jikia, MD, MPHView Slideset
KLKarine LacombeMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018HBV managment in HIV patients - Karine Lacombe, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Follow-Up of Sustained Virologic Responders with Hepatitis C/HIV Coinfection and Advanced Liver Disease | C. SoeiroView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Long-Term Changes of Liver Stiffness After the Use of All Oral DAA Regimens | Nicolás MerchanteView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018A Comparison of Single and Multiple Tablet Regiments for the Treatment of HCV Infection Among HIV Co-Infected Individuals | Astou ThiamView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018HCV care after cure- Raffaele Bruno, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Baseline Resistance-Guided Therapy Does Not Enhance the Response to Interferon-Free Treatment of HCV Infection in Real Life | Luis M. RealView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Real-life Results of Grazoprevir/Elbasvir in HCV-Infected PWID: The Zepalive Studi | Juan MacíasView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Response to Sofosbuvir/Ledipasvir for 8 or 12 Weeks in HCV-Monoinfected and HIV/HCV-Coinfected Patients in Clinical Practice | Anaïs CormaView Slideset
MPMarion PetersMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018Fibrosis Markers and Cirrhosis management in HIV patients | Marion Peters, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018NAFLD: diagnostics, management and screening- Juan Macías, MD, PhDView Slideset
JRJürgen RockstrohMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018HCV in 2018- Jürgen Rockstroh, MDView Slideset
